Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IONIS-FB-LRx in Primary IgA Nephropathy
NCT04014335Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Feb 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
A Phase 2 trial of sefaxersen in IgA nephropathy (IgAN), sponsored by Ionis Pharmaceuticals. Started Dec 2019; status: completed.
02
Drugs
sefaxersen
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT04014335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04014335.